^
Association details:
| Biomarker: | HER-2 mutation |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Tarlox (tarloxotinib bromide) (EGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Study of Tarloxotinib in Pts With NSCLC (EGFR Exon 20 Insertion, HER2-activating Mutations) & Other Solid Tumors With NRG1/ERBB Gene Fusions
Excerpt:
...- EGFR exon 20 insertion mutation (Cohort A) or HER2 activating mutation (Cohort B) or NRG1 or ERBB family gene fusions (Cohort C)...
Trial ID:
Source:
Title:
NSCLC Exon 20 or HER2-activating Mutations
Excerpt:
...- EGFR exon 20 insertion mutation (Cohort A) or HER2-activating mutation (Cohort B)...
Trial ID:
Less C2 evidence
Source:
Title:
LBA61 - First analysis of RAIN-701: Study of tarloxotinib in patients with non-small cell lung cancer (NSCLC) EGFR Exon 20 insertion, HER2-activating mutations & other solid tumours with NRG1/ERBB gene fusions
Published date:
09/19/2020
Excerpt:
Patients (pts) with advanced NSCLC harboring an EGFR Exon 20 insertion (Cohort A) or HER2 activating mutation (Cohort B) with progressive disease after platinum-based chemotherapy or with any solid tumors harboring an NRG1, EGFR, HER2 or HER4 fusion (cohort C) were eligible....23 pts (11 cohort A, 11 cohort B, 1 cohort C) were treated with tarloxotinib....In cohort A, the best response was stable disease (SD) in 6/11 (55%) and progressive disease (PD) in 5/11 (45%). In cohort B, 4/9 evaluable pts (44%) exhibited tumor reduction by RECIST and 2/9 pts experienced confirmed PR (22%), 4/9 (44%) pts had SD, and 3/9 (33%) pts had PD.
Trial ID:
